Jun 17, 2019
Zydus Announces Completion of Enrolment in EVIDENCES IV Phase 2 Clinical Trial of Saroglitazar Magnesium in NASH
Jun 11, 2019
NASH kNOWledge Joins Global International Nonalcoholic Steatohepatitis (NASH) DAY to Raise Disease Awareness
Jun 09, 2019
VeroScience Presents New Pipeline Data for Metabolic Disease Therapies at 2019 American Diabetes Association Meeting
Jun 05, 2019
Interim Data on Cirius Therapeutics' MSDC-0602K to be Presented at the American Diabetes Association Scientific Sessions
May 22, 2019
Scientists Identify New Therapeutic Target for Fatty Liver Disease
May 01, 2019
Akero Therapeutics Appoints Life Sciences Investment Banking Veteran Bill White as Chief Financial Officer and Head of Corporate Development
Apr 30, 2019
Galmed Pharmaceuticals to Report First Quarter 2019 Financial Results and Provide Business Update on Tuesday, May 7
Apr 18, 2019
Bioclinica Launches NAFLD/NASH Clinical Trials Practice
Apr 12, 2019
Cirius Therapeutics Announces Presentation of Interim Data from Phase 2b Clinical Study of MSDC-0602K at The International Liver Congress 2019
Apr 11, 2019
89bio Announces Preclinical Data That Demonstrate Potential Utility of BIO89-100 for Treatment of NASH
Apr 10, 2019
Second Edition Textbook, 'Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease,' Provides Roadmap for Preclinical and Clinical Research
Apr 09, 2019
Galmed Pharmaceuticals Announces Successful Completion of End of Phase 2 Meeting With FDA and Plan for Start of Phase 3
Apr 04, 2019
Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress(TM) 2019
Apr 01, 2019
DURECT to Present at the H.C. Wainwright Global Life Sciences Conference and Host an Upcoming KOL call on NASH
Mar 28, 2019
Pliant Therapeutics Presents Data in Human NASH Liver Tissue at The International Liver Congress 2019 Hosted by the European Association for the Study of the Liver (EASL)
Mar 27, 2019
Cirius Therapeutics to Present Preclinical Data for Lead Drug Candidate in NASH at The International Liver Congress
Mar 27, 2019
DURECT Announces Patient Enrollment in Phase 1b Clinical Trial of Oral DUR-928 in Patients with Non-Alcoholic Steatohepatitis (NASH)
Mar 26, 2019
The Kinetix Group and Consulting at McCann Health's Research Report on Quality Measures for Nonalcoholic Steatohepatitis (NASH) to Be Presented at ISPOR­ 2019
Mar 21, 2019
Lipocine to Participate at the ROTH Battle of the NASH Thrones Spring Investor Conference
Mar 20, 2019
Takeda and HemoShear Therapeutics Extend Exclusive Drug Discovery Partnership in Liver Diseases